What CEO Jason Okazaki called Assembly Biosciences Inc.’s “monumental” deal for new antivirals with Gilead Sciences Inc. brings $100 million right away, consisting of an $84.8 million up-front payment and a $15.2 million equity investment. Wall Street liked it, and shares of South San Francisco-based Assembly (NASDAQ:ASMB) closed Oct. 17 at $1.25, up 52 cents or 72%, on word of the 12-year arrangement. Gilead (NASDAQ:GILD) ended at $80.48, up $1.28. Read More
Monte Rosa Therapeutics Inc. has cut a deal with Roche Holding AG that brings the molecular glue degrader-based medicines developer an up-front $50 million and the possibility of more than $2 billion in milestone payments. The Boston-based company coupled the deal by releasing positive interim data from the phase I dose-escalation portion of its phase I/II open-label, multisite study of MRT-2359 in Myc-driven solid tumors. Read More
Danish obesity and diabetes drugmaker Novo Nordisk A/S is set to acquire the Singapore-based KBP Biosciences Co. Ltd.’s hypertension drug, ocedurenone (KBP-5074), for potentially $1.3 billion, creating a platform to increase its reach in the cardiovascular (CV) landscape beyond a crowding obesity market. Read More
The official end of the COVID-19 public health emergency in the U.S. in May did not mark the end of interest and investment in the area. In the shifting landscape, attention has pivoted to new markets, emerging strains, boosters, and the commercialization and distribution of COVID-19 vaccines and therapies. Read More
With an FDA approval decision on treosulfan possibly more than a year off, the U.S. Patent and Trademark Office granted Medac GmbH a third one-year extension of its method-of-use patent covering the drug, which is being developed as a conditioning agent in allogeneic hematopoietic stem cell transplantation.
Abbisko Therapeutics Co. Ltd. announced positive first-in-human data for its highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor, irpagratinib (ABSK-011), for treating advanced hepatocellular carcinoma with FGF19 overexpression, which is seen in roughly 30% of liver cancers. Read More
New hires and promotions in the biopharma industry, including: Cargo, Cartherics, Cognito, Epic, Fusion, Modifi, Olema, Pliant, Rockwell, Ten63, Titan, Vilya, Zydus, Zymeworks. Read More
New and updated clinical data presented by biopharma firms at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
, including: Aprea, Aulos, Avistone, Beyond Cancer, Black Diamond, Cogent, Omega, Ose, Puma, Revolution, Verastem. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aim, Bioaegis, Blue, Castlevax, Elevar, GRI, Immunos, Kyowa Kirin, Lumen, Lytix, Merck, Notable, Poolbeg, Revive, Sana, Seelos, Spark, Splicebio, VBL, Y-mabs. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Astrazeneca, Beigene, BMS, Bionomics, Cidara, Contrafect, Intellia, Merck & Co., Terns. Read More
